A daughter seeks advice after discovering her mother's retirement savings are far less than expected, having previously received a significant gift. The situation involves a substantial financial shortfall and a strained relationship due to the mother's pride and unwillingness to accept help. What options does the daughter have?

A class-action lawsuit alleges LifeMD (LFMD) misled investors about its financial performance. The suit, filed in the Eastern District of New York, follows a significant drop in LifeMD's stock price after disappointing Q2 2025 results. Hagens Berman is investigating the matter.

Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) benefits from Vale Base Metals' successful cobalt throughput test at the Voisey's Bay mine in Canada. The test yielded a high average throughput rate, boosting Ecora's cobalt stream revenue potential.

Biocodex, a French pharmaceutical company, is leading a €55 million Series B funding round for MRM Health, a Belgian biotech developing microbiome-based therapies. The investment, potentially reaching €30 million, underscores Biocodex's commitment to innovative treatments for inflammatory diseases.

Blue Moon Metals Inc. (TSXV: MOON; OTCQX: BMOOF) closed a US$5 million private placement with Oaktree Capital Management and secured a US$12.5 million bridge loan. This initial funding will support pre-construction activities for the Nussir copper project in Norway.

Frankfurt-based Nakiki SE will issue a bond to purchase Bitcoin, details of which will be revealed at a virtual roundtable on September 8th. The event will cover the bond's structure, Nakiki's investment strategy, and the bond's strategic role. Investors, analysts, and media are invited.

S&P 500 profit margins remained strong in Q2 despite tariffs, defying expectations. Howard Silverblatt of S&P Dow Jones Indices anticipates lower margins in Q3 as tariff costs are passed on and inventories are replenished. Inflationary effects are expected to peak about a year after tariff implementation.

500 Global and Creators HQ partnered to create the Creators Ventures Accelerator, a 10-week program supporting creator-led startups. The program aims to help creators build scalable businesses, leveraging 500 Global’s venture expertise and Creators HQ’s network.

The Trump administration appealed a lower court ruling on tariffs to the Supreme Court. The administration argues the president has the authority to impose tariffs under federal law, while opponents contend the tariffs harm businesses. The Supreme Court is expected to hear the case soon.

Giorgio Armani, the renowned Italian designer, passed away at 91. His fashion house, a multi-billion dollar empire built on understated elegance, confirmed his death at his home. Armani's influence extended beyond fashion, encompassing various businesses and philanthropic endeavors.

Concerns over Federal Reserve independence and rising inflation are prompting investors to consider diversifying into commodities, particularly gold. Goldman Sachs analysts predict significant gold price increases, potentially exceeding $4,500 per troy ounce. JPMorgan also sees gold as a key beneficiary of the current market climate.

Toll Brothers is launching Bethany Farms, a new luxury home community in Simpsonville, South Carolina. The development features spacious homes on half-acre lots, a community pool, and proximity to Greenville. Sales begin this fall.

Baker Tilly Capital secured funding for a new Pawnee Nation of Oklahoma behavioral health center. The facility addresses critical needs for opioid addiction, suicide prevention, and mental healthcare in a severely underserved rural area, creating jobs and improving access to care.

Logile and Connors Group announced a strategic partnership to improve fresh food management for grocery retailers. The collaboration combines Logile's AI-powered software with Connors Group's consulting expertise to reduce waste and boost profitability. This aims to help retailers navigate the complexities of fresh food retail.

US jobless claims unexpectedly climbed to 237,000 last week, exceeding economist projections. This increase, reported by MarketWatch, marks the highest level since late June and signals potential shifts in the labor market. Further analysis is needed to determine the long-term implications.

Artelo Biosciences (ARTL) priced its public offering of 640,924 shares of common stock at $4.40 per share and pre-funded warrants. The offering is expected to generate approximately $3 million in gross proceeds before expenses. The offering is expected to close on September 5th, 2025.